What is Wedbush’s Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Wedbush issued their Q1 2025 earnings per share estimates for shares of Wave Life Sciences in a research note issued to investors on Tuesday, April 8th. Wedbush analyst Y. Zhong expects that the company will post earnings of ($0.27) per share for the quarter. Wedbush currently has a “Outperform” rating and a $18.00 price objective on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.04) EPS and FY2026 earnings at ($1.14) EPS.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to analysts’ expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

Several other brokerages also recently commented on WVE. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 26th. StockNews.com raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Jefferies Financial Group assumed coverage on Wave Life Sciences in a report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.18.

Wave Life Sciences Price Performance

Shares of NASDAQ WVE opened at $5.48 on Friday. The company has a 50 day simple moving average of $9.56 and a 200 day simple moving average of $11.68. Wave Life Sciences has a 1 year low of $4.25 and a 1 year high of $16.74. The firm has a market cap of $841.10 million, a PE ratio of -4.94 and a beta of -0.93.

Insider Activity

In other news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now owns 338,351 shares of the company’s stock, valued at $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the transaction, the director now directly owns 16,115 shares in the company, valued at $157,443.55. This represents a 39.45 % decrease in their position. The disclosure for this sale can be found here. Insiders own 29.10% of the company’s stock.

Hedge Funds Weigh In On Wave Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WVE. GF Fund Management CO. LTD. bought a new stake in shares of Wave Life Sciences during the fourth quarter worth $40,000. Quarry LP purchased a new stake in Wave Life Sciences in the 4th quarter valued at about $62,000. KBC Group NV bought a new position in Wave Life Sciences in the 4th quarter worth about $67,000. Summit Investment Advisors Inc. increased its position in shares of Wave Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after acquiring an additional 2,308 shares during the period. Finally, Orion Portfolio Solutions LLC bought a new stake in shares of Wave Life Sciences during the third quarter valued at approximately $123,000. 89.73% of the stock is owned by institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.